Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Overall Survival Improvement Following ALLO-SCT in Patients Older THAN 60 YEARS: A Gruppo Italiano Trapianto DI Midollo Osseo (GITMO) Registry Study

Michele Malagola, Nicola Polverelli, Massimo Martino, Vicky Rubini, Maria Teresa Lupo Stanghellini, Francesca Patriarca, Renato Fanin, Benedetto Bruno, Luisa Giaccone, Danilo Giuseppe Faraci, Giovanni Grillo, Stefania Bramanti, Luca Castagna, Paolo Bernasconi, Anna Amelia Colombo, Marco De Gobbi, Paolo Nicoli, Annalisa Natale, Stella Santarone, Elisabetta Terruzzi, Attilio Olivieri, Ilaria Scortechini, Patrizia Chiusolo, Elisabetta Metafuni, Angelo Michele Carella, Emanuela Merla, Marco Casini, Irene M Cavattoni, Mario Arpinati, Chiara Nozzoli, Ilaria Cutini, Patrizio Mazza, Annamaria Mazzone, Simona Bassi, Francesco Onida, Giorgia Saporiti, Filippo Antonio Canale, Adriana Vacca, Eugenia Piras, Piero Galieni, Sadia Falcioni, Mario Luppi, Giulia Debbia, Anna Paola Iori, Ursula La Rocca, Vincenzo Pavone, Anna Mele, Cristina Skert, Francesca Carobolante, Paola Carluccio, Carlo Borghero, Francesca Elice, Anna Proia, Fulvia Fanelli, Carmine Selleri, Nicoletta Sacchi, Sonia Mammoliti, Elena Oldani, Fabio Ciceri, Francesca Bonifazi, Domenico Russo

Blood (2021) 138 (Supplement 1): 1786.

https://doi.org/10.1182/blood-2021-145970

Published: 2021

Journal Articles

Rituximab Maintenance Treatment for a Maximum of 5 Years In Follicular Lymphoma: Safety Analysis of the Randomized Phase III Trial SAKK 35/03

Christian J. Taverna, MD, Simona Bassi, Felicitas Hitz, Walter Mingrone, Thomas Pabst, Lidija Cevreska, MD, PhD, Auro del Giglio, MD, Daniel A. Vorobiof, Mathew Simcock, Michele Ghielmini, MD

Blood (2010) 116 (21): 1802.

https://doi.org/10.1182/blood.V116.21.1802.1802

Published: 2010

Journal Articles

A New Induction Combination Therapy (ThalDoDex) for Multiple Myeloma. Preliminary Results of a Phase II Study

Simona Sammassimo, Alberto Agazzi, Simona Bassi, Liliana Calabrese, Paola Bertazzoni, Anna Vanazzi, Angelo Gardellini, Federica Gigli, Giovanna Andreola, Giovanni Martinelli, MD

Blood (2010) 116 (21): 5030.

https://doi.org/10.1182/blood.V116.21.5030.5030

Published: 2010

Journal Articles

Rituximab Plus Chlorambucil Compared with Chlorambucil and Prednisone In Patients with Untreated Follicular Lymphoma

Simona Bassi, Simona Sammassimo, Federica Gigli, Giancarlo Pruneri, Paola Bertazzoni, Jessica Quarna, Emilia Cocorocchio, Daniele Laszlo, Mara Negri, Maria Lionetti, Anna Vanazzi, Alessandra Alietti, Alberto Agazzi, Angelo Gardellini, Giovanna Andreola, Lorenzo Preda, Rocco Pastano, Giovanni Martinelli, MD

Blood (2010) 116 (21): 3956.

https://doi.org/10.1182/blood.V116.21.3956.3956

Published: 2010

Journal Articles

Rituximab and Chlorambucil as Front-Line Treatment in Untreated Follicular Lymphoma: a Combination with a Durable Response and Low Toxicity Profile.

Simona Bassi, MD, Luca Nassi, MD, Giancarlo Pruneri, MD, Simona Sammassimo, MD, Paola Bertazzoni, MD, Federica Gigli, MD, Anna Vanazzi, MD, Emilia Cocorocchio, MD, Patrizia Mancuso, Cristina Rabascio, Maria Teresa Lionetti, Daniele Laszlo, MD, Giovanni Martinelli, MD

Blood (2009) 114 (22): 3754.

https://doi.org/10.1182/blood.V114.22.3754.3754

Published: 2009

Journal Articles

Rituximab and 2-Cda Activity in CLL/SLL Patients: An Update of Pharmacogenomic and Clinical Results

Paola Bertazzoni, Cristina Rabascio, Liliana Calabrese, Federica Gigli, Simona Bassi, MD, Luca Nassi, Simona Sammassimo, Sara Steffanoni, Davide Radice, Angelica Calleri, Emilia Cocorocchio, Daniele Laszlo, Giovanni Martinelli

Blood (2008) 112 (11): 3171.

https://doi.org/10.1182/blood.V112.11.3171.3171

Published: 2008

Journal Articles

Interim 18 f[FDG] Positron Emission Tomography in Patients with Diffuse Large B-Cell Lymphoma

Federica Gigli, Luca Nassi, Mara Negri, Laura Travaini, Sara Steffanoni, Sarah Jane Liptrott, Patrizia Mancuso, Paola Bertazzoni, Simona Bassi, MD, Liliana Calabrese, Emilia Cocorocchio, Giovanni Martinelli

Blood (2008) 112 (11): 3607.

https://doi.org/10.1182/blood.V112.11.3607.3607

Published: 2008

Journal Articles

Evolving First-Line Treatments -from Chemotherapy to Immunotherapy Alone- in 143 Consecutive Follicular Lymphoma Patients Treated in the Last 14 Years at the European Institute of Oncology, Milano

Simona Bassi, MD, Federica Gigli, Cristina Rabascio, Simona Sammassimo, Patrizia Mancuso, Emilia Cocorocchio, Paola Bertazzoni, Daniele Laszlo, Giancarlo Pruneri, Liliana Calabrese, Maria Teresa Lionetti, Anna Vanazzi, MD, Alessandra Alietti, Luca Nassi, Alberto Agazzi, Rocco Pastano, Fedro Alessandro Peccatori, Giovanni Martinelli

Blood (2008) 112 (11): 5016.

https://doi.org/10.1182/blood.V112.11.5016.5016

Published: 2008

Journal Articles

Combined VBM Chemotherapy and Involved Field (IF) Radiotherapy in Early Stage Hodgkin’s Lymphoma (HL): A Single Centre Experience.

Emilia Cocorocchio, MD, Fedro A. Peccatori, MD, Federica Gigli, MD, Simona Bassi, MD, Luca Nassi, MD, Liliana Calabrese, DSc, Laura Travaini, MD, Gaia Piperno, MD, Lorenzo Preda, MD, Giancarlo Pruneri, MD, Sarah J. Liptrott, BN, Alessandra Alietti, MD, Giovanni Martinelli, MD

Blood (2007) 110 (11): 4463.

https://doi.org/10.1182/blood.V110.11.4463.4463

Published: 2007

Journal Articles

Continuous Immuno-Chemotherapy Followed by High Dose and Autologous Cell Transplantation May Improve the Event-Free-Survival in Mantle Cell Lymphoma Patients. Experience at the European Institute of Oncology in Milan.

Simona Bassi, MD, Alessandra Alietti, MD, Chiara Corsini, DSc, Federica Gigli, MD, Paola Bertazzoni, MD, Cristina Rabascio, DSc, Patrizia Mancuso, DSc, Emilia Cocorocchio, MD, Daniele Laszlo, MD, Giancarlo Pruneri, MD, Lorenzo Preda, MD, Sarah J. Liptrott, BN, Rosaria Cascio, PH, Francesco Bertolini, MD, Giovanni Martinelli, MD

Blood (2007) 110 (11): 5116.

https://doi.org/10.1182/blood.V110.11.5116.5116

Published: 2007

Journal Articles

Impact of Age in the Outcome of Patients with Chronic Myeloid Leukemia in Late Chronic Phase: Clinical and Molecular Results of a Phase II Study of the GIMEMA CML Working Party.

Giovanni Martinelli, Francesca Palandri, Ilaria Iacobucci, Simona Bassi, Fausto Castagnetti, Marilina Amabile, Daniela Cilloni, Angela Poerio, Simona Soverini, Giovanna Rege-Cambrin, Franco Iuliano, Giuliana Alimena, Roberto Latagliata, Nicoletta Testoni, Fabrizio Pane, Giuseppe Saglio, Gianantonio Rosti, Michele Baccarani

Blood (2006) 108 (11): 4805.

https://doi.org/10.1182/blood.V108.11.4805.4805

Published: 2006

Journal Articles

High Dose Chemotherapy with Autologous Stem Cell Support Is Effective in Resistant and Refractory Hodgkin Lymphoma. A Single Center Analysis.

Emilia Cocorocchio, MD, Fedro Peccatori, MD, Simona Bassi, MD, Federica Gigli, MD, Davide Radice, Giancarlo Pruneri, MD, Cristina Rabascio, Liliana Calabrese, Giovanni Martinelli, MD

Blood (2005) 106 (11): 5506.

https://doi.org/10.1182/blood.V106.11.5506.5506

Published: 2005

Journal Articles

Imatinib and pegylated human recombinant interferon-α2b in early chronic-phase chronic myeloid leukemia

Blood (2004) 104 (13): 4245–4251.

https://doi.org/10.1182/blood-2004-03-0826

Published: 2004

Journal Articles

A New Abl Kinase Inhibitor (AMN107) Has In Vitro Activity on CML Ph+Blast Cells Resistant to Imatinib.

Giovanni Martinelli, Alberto M. Martelli, Tiziana Grafone, Gianantonio Rosti, Irina Mantovani, Alessandra Cappellini, Pier Luigi Tazzari, Emanuela Ottaviani, Matteo Renzulli, Marilina Amabile, Angela Poerio, Simona Soverini, Carolina Terragna, Cristian Taccioli, Simona Bassi, Michele Baccarani

Blood (2004) 104 (11): 4687.

https://doi.org/10.1182/blood.V104.11.4687.4687

Published: 2004

Journal Articles

Down Regulation of TOPK, PBX3, SRPK, DDX21 and CLC Genes in Newly Diagnosed, Early-Chronic Phase Chronic Myeloid Leukemia Patients Treated with Imatinib Mesylate.

Blood (2004) 104 (11): 4650.

https://doi.org/10.1182/blood.V104.11.4650.4650

Published: 2004

Journal Articles

Imatinib in the Treatment of CML Patients ≥ 65 Years Old in Late Chronic Phase: Results of a Phase II Study of the GIMEMA CML Working Party.

Simona Bassi, MD, Fausto Castagnetti, MD, Marilina Amabile, BD, Barbara Giannini, BD, Daniela Cilloni, MD, Barbara Izzo, BD, Antonio De Vivo, MD, Simona Luatti, BD, Nicoletta Testoni, BD, Giovanna Rege-Cambrin, MD, Ilaria Iacobucci, BD, Enrico Gottardi, BD, Fabrizio Pane, MD, Francesco Salvatore, MD, Alessandra Dorigo, MD, Giuseppe Saglio, MD, Giovanni Martinelli, MD, Gianantonio Rosti, MD, Michele Baccarani, MD

Blood (2004) 104 (11): 2935.

https://doi.org/10.1182/blood.V104.11.2935.2935

Published: 2004

Journal Articles

Prediction of Response to Imatinib by Prospective Quantitation of BCR-ABL Transcript in Late Chronic Phase Chronic Myeloid Leukemia PatientsBy GIMEMA Working Party on CML.

Blood (2004) 104 (11): 4672.

https://doi.org/10.1182/blood.V104.11.4672.4672

Published: 2004

Journal Articles

ABL Mutations in Late-Chronic Phase Chronic Myeloid Leukemia Patients with Cytogenetic Refractoriness to Imatinib Are Associated with a Greater Likelihood of Progression to Blast Crisis and Shorter Survival. on behalf of the GIMEMA Working Party on Chronic Myeloid Leukemia.

Blood (2004) 104 (11): 1005.

https://doi.org/10.1182/blood.V104.11.1005.1005

Published: 2004

Journal Articles

Molecular response to imatinib in late chronic-phase chronic myeloid leukemia

Blood (2004) 103 (6): 2284–2290.

https://doi.org/10.1182/blood-2003-07-2575

Published: 2004

NARROW

Overall Survival Improvement Following ALLO-SCT in Patients Older THAN 60 YEARS: A Gruppo Italiano Trapianto DI Midollo Osseo (GITMO) Registry Study

Rituximab Maintenance Treatment for a Maximum of 5 Years In Follicular Lymphoma: Safety Analysis of the Randomized Phase III Trial SAKK 35/03

A New Induction Combination Therapy (ThalDoDex) for Multiple Myeloma. Preliminary Results of a Phase II Study

Rituximab Plus Chlorambucil Compared with Chlorambucil and Prednisone In Patients with Untreated Follicular Lymphoma

Rituximab and Chlorambucil as Front-Line Treatment in Untreated Follicular Lymphoma: a Combination with a Durable Response and Low Toxicity Profile.

Rituximab and 2-Cda Activity in CLL/SLL Patients: An Update of Pharmacogenomic and Clinical Results

Interim 18 f[FDG] Positron Emission Tomography in Patients with Diffuse Large B-Cell Lymphoma

Evolving First-Line Treatments -from Chemotherapy to Immunotherapy Alone- in 143 Consecutive Follicular Lymphoma Patients Treated in the Last 14 Years at the European Institute of Oncology, Milano

Combined VBM Chemotherapy and Involved Field (IF) Radiotherapy in Early Stage Hodgkin’s Lymphoma (HL): A Single Centre Experience.

Continuous Immuno-Chemotherapy Followed by High Dose and Autologous Cell Transplantation May Improve the Event-Free-Survival in Mantle Cell Lymphoma Patients. Experience at the European Institute of Oncology in Milan.

Impact of Age in the Outcome of Patients with Chronic Myeloid Leukemia in Late Chronic Phase: Clinical and Molecular Results of a Phase II Study of the GIMEMA CML Working Party.

High Dose Chemotherapy with Autologous Stem Cell Support Is Effective in Resistant and Refractory Hodgkin Lymphoma. A Single Center Analysis.

Imatinib and pegylated human recombinant interferon-α2b in early chronic-phase chronic myeloid leukemia

A New Abl Kinase Inhibitor (AMN107) Has In Vitro Activity on CML Ph+Blast Cells Resistant to Imatinib.

Down Regulation of TOPK, PBX3, SRPK, DDX21 and CLC Genes in Newly Diagnosed, Early-Chronic Phase Chronic Myeloid Leukemia Patients Treated with Imatinib Mesylate.

Imatinib in the Treatment of CML Patients ≥ 65 Years Old in Late Chronic Phase: Results of a Phase II Study of the GIMEMA CML Working Party.

Prediction of Response to Imatinib by Prospective Quantitation of BCR-ABL Transcript in Late Chronic Phase Chronic Myeloid Leukemia PatientsBy GIMEMA Working Party on CML.

ABL Mutations in Late-Chronic Phase Chronic Myeloid Leukemia Patients with Cytogenetic Refractoriness to Imatinib Are Associated with a Greater Likelihood of Progression to Blast Crisis and Shorter Survival. on behalf of the GIMEMA Working Party on Chronic Myeloid Leukemia.

Molecular response to imatinib in late chronic-phase chronic myeloid leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only